The Lynx Group
Cholangiocarcinoma News

Zanidatamab (ZW25) in HER2-Positive Biliary Tract Cancers: Results from a Phase 1 Study

2021 Year in Review: Cholangiocarcinoma — December 17, 2021

Results from a first-in-human, phase 1 study have shown that the bispecific HER2-targeted antibody zanidatamab is well-tolerated and has antitumor activity in patients with HER2-overexpressing biliary tract cancers.

Approximately 5% to 19% of all biliary tract cancers (BTCs) show overexpression/amplification of HER2. The bispecific HER2-targeted antibody zanidatamab was evaluated in a first-in-human, 3-part, phase 1 study (ClinicalTrials.gov Identifier: NCT02892123; ZWI-ZW25-101) in HER2-overexpressing cancers, including BTCs. Results of the expansion cohort of this phase 1 study were presented at the 2021 American Society of Clinical Oncology Annual Meeting.

The BTC cohort of this phase 1 study included patients with BTC that was centrally confirmed HER2-overexpressing (ie, immunohistochemistry [IHC] 3+ or IHC 2+/fluorescence in situ hybridization [FISH]+), showed disease progression after standard-of-care therapy, and had measurable disease per RECIST version 1.1. Eligible patients were treated with zanidatamab 20 mg/kg every 2 weeks. Tumor assessments were performed every 8 weeks. The data cutoff date was July 28, 2020.

In the dose-escalation part 1 of the study, the recommended dose of zanidatamab monotherapy was determined to be 10 mg/kg weekly and 20 mg/kg every 2 weeks. In the expansion part 2 of the study, a total of 21 patients with BTC were enrolled and received the recommended dose of 20 mg/kg every 2 weeks. The median age of the expansion cohort was 63 years. The majority of the participants were females, and the median number of prior systemic therapies was 2.5, including 5 patients who had received prior trastuzumab. In the BTC cohort, 11 participants had gallbladder cancer, 5 had intrahepatic cholangiocarcinoma, and 4 had extrahepatic cholangiocarcinoma.

Of the 20 patients in the safety population, 14 (70%) individuals experienced zanidatamab-related adverse events (AEs). The most common treatment-related AEs were diarrhea (45%) and infusion-related reactions (30%). No grade ≥3 zanidatamab-related AEs were reported.

Of the 17 patients who were evaluable for response, the confirmed overall response rate was 47% (n = 8), all of which were partial responses. Five additional patients achieved stable disease, for a disease control rate of 65% (n = 11). The median duration of response was 6.6 months.

Based on these results, the researchers concluded that zanidatamab is well-tolerated and active in patients with HER2-overexpressing BTC. An ongoing global phase 2b study (ClinicalTrials.gov Identifier: NCT04466891; HERIZON-BTC-01) is further evaluating zanidatamab in patients with advanced HER2-positive BTC who have progressed after treatment with a gemcitabine-containing regimen.

Source: Meric-Bernstam F, Hanna DL, El-Khoueiry AB, et al. Zanidatamab (ZW25) in HER2-positive biliary tract cancers (BTCs): results from a phase I study. J Clin Oncol. 2021;39(suppl_3):299-299.

Related Items

A Phase 1/2 Study of the Safety and Efficacy of the Arginase Inhibitor INCB001158 plus Chemotherapy in Patients with Advanced Biliary Tract Cancer
2021 Year in Review: Cholangiocarcinoma
Results of an open-label, phase 1/2 study indicate that addition of INCB001158 to the standard gemcitabine/cisplatin backbone was tolerable, did not result in significant additional toxicity, and showed modest clinical activity in the biliary tract cancers cohort.
Lenvatinib plus Pembrolizumab for Patients with Previously Treated Biliary Tract Cancers in the Multicohort Phase 2 LEAP-005 Study
2021 Year in Review: Cholangiocarcinoma
Results of the phase 2 LEAP-005 study suggest that lenvatinib plus pembrolizumab shows promising antitumor activity and manageable toxicity in previously treated patients with advanced biliary tract cancers.
Phase 2a MyPathway Results of Pertuzumab plus Trastuzumab for the Treatment of HER2-Positive Metastatic Biliary Tract Cancer
2021 Year in Review: Cholangiocarcinoma
Results of an ongoing, phase 2a, multiple-basket study (MyPathway) showed that dual HER2-targeted therapy with pertuzumab plus trastuzumab was well-tolerated in patients with previously treated HER2-positive metastatic biliary tract cancer.
Liposomal Irinotecan in Combination with 5-Fluorouracil and Leucovorin for Patients with Metastatic Biliary Tract Cancer After Progression on Gemcitabine plus Cisplatin: A Multicenter, Comparative, Randomized, Phase 2b Study (NIFTY)
2021 Year in Review: Cholangiocarcinoma
Results of the NIFTY trial demonstrated that liposomal irinotecan plus 5-fluorouracil and leucovorin significantly improved efficacy outcomes compared with 5-fluorouracil plus leucovorin alone in patients with biliary tract cancer who progressed on prior gemcitabine/cisplatin, with a manageable adverse event profile.
Liposomal Irinotecan plus 5-Fluorouracil/Leucovorin or Gemcitabine/Cisplatin in Patients with Advanced Biliary Tract Cancer (NIFE Trial)
2021 Year in Review: Cholangiocarcinoma
The phase 2 NIFE study compared a liposomal irinotecan plus fluorouracil and leucovorin regimen with standard-of-care gemcitabine/cisplatin in patients with advanced biliary tract cancer.
Does Adjuvant Chemoradiation Benefit Patients with Lymph Node–Positive Biliary Tract Cancer? A Secondary Analysis of SWOG S0809
2021 Year in Review: Cholangiocarcinoma
Results of the secondary analysis of the SWOG S0809 trial indicate that nodal status did not impact survival outcomes achieved with adjuvant chemoradiation postresection in patients with extrahepatic CCA or gallbladder cancer.
Role of ctDNA to Predict Risk for Recurrence Following Potentially Curative Resection of Biliary Tract and Pancreatic Malignancies
2021 Year in Review: Cholangiocarcinoma
Results of a pilot study demonstrate the feasibility of ctDNA testing and the prognostic value of ctDNA following potentially curative resection in patients with pancreatic/biliary tract malignancies.
Efficacy and Safety of Nab-Paclitaxel plus Gemcitabine/Cisplatin in Korean Patients with Advanced Biliary Tract Cancers
2021 Year in Review: Cholangiocarcinoma
Real-world retrospective evidence from Korean patients with advanced biliary tract cancer indicates that efficacy and safety with nab-paclitaxel plus gemcitabine/cisplatin combination were consistent with those previously reported in clinical trials.
First-Line Immunotherapy plus Chemotherapy Significantly Improves Survival in Advanced Biliary Tract Cancer
Web Exclusives
On October 25, 2021, AstraZeneca announced high-level positive results from the phase 3 clinical trial TOPAZ-1, demonstrating that adding the immunotherapy durvalumab (Imfinzi) to first-line standard-of-care chemotherapy leads to a statistically significant and clinically meaningful overall survival (OS) benefit versus chemotherapy alone in patients with advanced biliary tract cancer.
Hot Topics in Cholangiocarcinoma and Biliary Tract Cancers: ASCO Highlights
September/October 2021, Vol 2, No 3
At the CCA Summit during the 2021 Annual Meeting of the American Society of Clinical Oncology (ASCO), Mitesh J. Borad, MD, Associate Professor of Medicine, Mayo Clinic, Phoenix, AZ, reviewed some of the key topics presented at ASCO 2021 related to cholangiocarcinoma (CCA) and other biliary tract cancers. Before turning to the specific presentations, Dr Borad welcomed the May 28, 2021, FDA approval of infigratinib (Truseltiq) for patients with advanced or metastatic CCA and FGFR2 fusions or rearrangements. Infigratinib follows pemigatinib (Pemazyre) as the second targeted therapy now available for this patient population.

Subscribe Today!

To sign up for our newsletter or print publications, please enter your contact information below.

I'd like to receive: